GYRE_OUT_1 [2025-04-04 06:11:40 -0400] 3782 Bytes | 1021 tokens | Cum: 1021 tkns (12.76% of 8k)
==========================================================================

Booyah, my friends! It's already 6:11:39 AM on Fri Apr 04, 2025 -0400, and I've got my eyes locked on Gyre Therapeutics (GYRE), pushing up to 10.39 from 6.8. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Gyre Therapeutics (GYRE)
IPO: 2023-10-31 (1 Year Ago)
Market Cap: $600,055,753
Shares Outstanding: 85,820,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Here’s the first list of news for Gyre Therapeutics:

C1 - Mar-31-25 07:00AM - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
C2 - Mar-27-25 07:00AM - Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
C3 - Mar-21-25 09:14AM - Gyre: Intriguing Upcoming Data Catalyst, But I'm Still On Sidelines
C4 - Mar-17-25 04:15PM - Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
C5 - Jan-06-25 07:00AM - Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
C6 - Nov-13-24 06:00AM - Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
C7 - Oct-22-24 04:05PM - Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis
C8 - Oct-01-24 04:05PM - Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference

Prior AI Reports for GYRE:
1. 2025-04-02 – Score: 1 – Target: 7.3694 – Highs: 7.6200 / 6.9600 / –
despite-market-volatility-insider-confidence-signals-potential-upside
2. 2025-03-19 – Score: 45 – Target: 10.5000 – Highs: 10.3700 / 10.6000 / 10.13
solid-sales-growth-amidst-short-term-performance-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Gyre Therapeutics (GYRE).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

GYRE_OUT_3 [2025-04-04 06:11:48 -0400] 1099 Bytes | 339 tokens | Cum: 1363 tkns (17.04% of 8k)
==========================================================================

Showing C4 (chunk 1 of 11): C4:
**Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update**
Date: Mar-17-25 04:15PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/17/3044101/0/en/Gyre-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

March 17, 2025 16:15 ET| Source:Gyre Therapeutics Inc.Gyre Therapeutics Inc.

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025

Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia expected in 2025

Initiation of U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis expected in 2025

Full year 2025totalrevenue guidance of $118 to $128 million

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre T

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_5 [2025-04-04 06:11:48 -0400] 948 Bytes | 296 tokens | Cum: 1804 tkns (22.55% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T08:11:53Z - Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Here's Why...
A2 - 2025-04-02T14:13:46Z - Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Mo...
A3 - 2025-04-01T19:31:15Z - Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% - Time to Sell?...
A4 - 2025-03-31T16:26:06Z - GYRE Stock Hits 52-Week Low at $8.26 Amid Market Challenges By Investing.com...
A5 - 2025-03-31T11:28:44Z - Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Onco...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GYRE_OUT_7 [2025-04-04 06:11:52 -0400] 1098 Bytes | 335 tokens | Cum: 2141 tkns (26.76% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low - Here's Why**Date: 2025-04-02Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/gyre-therapeutics-nasdaqgyre-sets-new-1-year-low-heres-why-2025-04-01/Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $7.00 and last traded at $7.72, with a volume of 411920 shares traded. The stock had previously closed at $9.11.

Separately, Noble Financial assumed coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating for the company.

Read Our Latest Research Report on GYRE

The firm has a market cap of $722.68 million, a price-to-earnings ratio of 154.40 and a beta of 1.93. The business has a 50-day moving average of $1

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_9 [2025-04-04 06:11:53 -0400] 1018 Bytes | 299 tokens | Cum: 2533 tkns (31.66% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-18T20:05:00Z - Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
B2 - 2024-05-28T20:05:00Z - Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
B3 - 2024-05-09T20:10:00Z - Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
B4 - 2024-04-11T17:33:07Z - Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2024-04-11T14:01:51Z - Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
B6 - 2024-03-26T10:00:00Z - Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GYRE_OUT_11 [2025-04-04 06:11:57 -0400] 580 Bytes | 168 tokens | Cum: 2703 tkns (33.79% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/18/2900811/0/en/Gyre-Therapeutics-Announces-Publication-in-Journal-of-Gastroenterology-and-Hepatology.htmlGyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_13 [2025-04-04 06:11:58 -0400] 1082 Bytes | 282 tokens | Cum: 3096 tkns (38.70% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-17 10-K Item 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included el...

S5 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furni...

S6 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Gyre Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2024 and other matters described. A copy of the press release is furni...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GYRE_OUT_15 [2025-04-04 06:12:02 -0400] 1098 Bytes | 236 tokens | Cum: 3334 tkns (41.68% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled Risk Factors. You should carefully read the Cautionary Note About Forward-Looking Statements and Risk Factors s

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GYRE_OUT_17 [2025-04-04 06:12:15 -0400] 6267 Bytes | 1773 tokens | Cum: 5205 tkns (65.06% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+------------------------+
| Volume: 187,590 | Perf Month: -38.85% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 135.47K | Perf Quarter: -43.80% | Short Float: 9.38% | ROE: - |
+---------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 1.39 | Index: RUT | Short Ratio: 11.27 | ROI: 18.82% |
+---------------------+-----------------------+------------------------+------------------------+
| RSI (14): 33.16 | Market Cap: 587.06M | Short Interest: 1.53M | Sales Surprise: 18.60% |
+---------------------+-----------------------+------------------------+------------------------+
| ATR (14): 1.12 | Shs Outstand: 86.31M | Beta: 1.90 | EPS Surprise: -100.00% |
+---------------------+-----------------------+------------------------+------------------------+
| SMA20: -29.35% | Shs Float: 16.27M | Sales Q/Q: - | P/E: 57.05 |
+---------------------+-----------------------+------------------------+------------------------+
| SMA50: -37.20% | Inst Own: 2.07% | Sales past 5Y: 246.63% | Earnings: Mar 17 AMC |
+---------------------+-----------------------+------------------------+------------------------+
| SMA200: -43.76% | Insider Own: 81.16% | Employees: 5 | |
+---------------------+-----------------------+------------------------+------------------------+
| Perf Week: -25.19% | Insider Trans: -0.17% | Debt/Eq: 0.03 | |
+---------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-21
- Common Stock: 174 shares at $10 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-19
- Common Stock: 2000 shares at $10.13 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $10.09 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-17
- Common Stock: 2000 shares at $12.09 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 242 shares at $10.24 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

Inside Trans: GYRE THERAPEUTICS, INC. (GYRE) by Ma Songjiang (President) on 2025-03-13
- Common Stock: 2000 shares at $11.8 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Common Stock: 2000 shares at $12.31 (I) Footnote: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 105757000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 17898000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6.8
Average Volume: 240643.82
30-Day High: 12.28
30-Day Low: 6.41

[Detailed Financials: TTM 2024]
- Total Assets: $125,406,000.0
- Total Liabilities: $27,004,000.0
- Total Equity: $98,402,000.0
- Current Assets: $64,786,000.0
- Current Liabilities: $19,516,000.0

[Income Statement: TTM 2024]
- Revenue: $105,757,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.14

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-21,423,000.0

[Detailed Financials: FY 2024]
- Total Assets: $125,406,000.0
- Total Liabilities: $27,004,000.0
- Total Equity: $98,402,000.0
- Current Assets: $64,786,000.0
- Current Liabilities: $19,516,000.0

[Income Statement: FY 2024]
- Revenue: $105,757,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 0.14

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-21,423,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

GYRE_OUT_19 [2025-04-04 06:12:17 -0400] 687 Bytes | 169 tokens | Cum: 5676 tkns (70.95% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

GYRE_IN_21 [2025-04-04 06:12:17 -0400] 126 Bytes | 29 tokens | Cum: 5735 tkns (71.69% of 8k)
==========================================================================

====================================
[2025-04-04 06:12:17] # Analysis Completed
Elapsed Time: 38.29 seconds